Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.79 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.79 |
| ▸ | RAF1 | P04049 | 1/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.79 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.79 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.79 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.79 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.79 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.79 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18088593 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL19261421 | 0.89 | MAP2K1 (0.66) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL13529672 | 0.89 | MAP2K1 (0.76) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| Ci-1040 SCHEMBL29381365 | 0.88 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| Ci-1040 SCHEMBL570330 | 0.88 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| Ci-1040 SCHEMBL29355105 | 0.88 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6944326 | 0.88 | MAP2K1 (0.75) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6943891 | 0.87 | MAP2K1 (0.74) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL22822261 | 0.87 | MAP2K1 (0.60) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL6944061 | 0.86 | MAP2K1 (0.73) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201198-A1 | METHODS OF TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022255738-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERTROPHIC SCAR AND KELOID, COMPRISING CI-1040, AZD6482, OR COMBINATION THEREOF AS ACTIVE INGREDIENT | 주식회사 아론티어 | 2022-12-08 | — | — | WO | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11135263-B2 | Novel-anti-infective strategy against influenza virus and S. aureus coinfections | ATRIVA THERAPEUTICS GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| EP-2548894-A1 | Pharmaceutical compositions with enhanced performance | Bend Research, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201198-A1 | METHODS OF TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | MAP2K1 19/4885MAP2K2 27/4885RAF1 10/4885 |
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | MAP2K1 4810/4885MAP2K2 4749/4885RAF1 2779/4885 |
| US-11135263-B2 | Novel-anti-infective strategy against influenza virus and S. aureus coinfections | MAPK1, MAP2K1, MAP2K6 | MAP2K1 2/4885MAP2K2 11/4885RAF1 115/4885 |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885RAF1 34/4885 |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885RAF1 36/4885 |
| US-11161845-B2 | Pyrrolopyridine-aniline compounds for treatment of dermal disorders | POLR1C, TYR, PAH | MAP2K1 435/4885MAP2K2 263/4885RAF1 69/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | MAP2K1 449/4885MAP2K2 250/4885RAF1 320/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MAP2K1 4785/4885MAP2K2 4715/4885RAF1 2627/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885RAF1 34/4885 |
| US-20220033399-A1 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | POLR1C, TYR, PAH | MAP2K1 470/4885MAP2K2 286/4885RAF1 68/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | MAP2K1 3724/4885MAP2K2 3349/4885RAF1 1304/4885 |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | PIK3CA, PNKP, PLK1 | MAP2K1 440/4885MAP2K2 222/4885RAF1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.